How much is Sunway worth?
As of July 13, 2026, Supernus Pharmaceuticals (SUPN) holds a market capitalization of approximately $2.75 billion. This valuation indicates the total market value of all outstanding shares for this specialty pharmaceutical company, which focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its market worth is heavily influenced by the performance of its core product portfolio, the progress of its clinical-stage pipeline, and investor expectations regarding future drug approvals and patent protections. As is common for companies in the pharmaceutical industry, the stock price and subsequent market capitalization can be quite sensitive to news regarding clinical trial results, FDA regulatory decisions, and the competitive landscape for its specific therapeutic areas, making the $2.75 billion figure a snapshot of its current public equity valuation.
Related FAQs
Synaptics Incorporated (SYNA) has demonstrated strong and dynamic stock performance recently, outperforming broader semiconductor and technology sector benchmarks over multi-month horizons.